You just read:

Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints

News provided by

Ionis Pharmaceuticals, Inc.

May 15, 2017, 07:00 ET